Eton Pharmaceuticals Announces Submission of NDA for ET-600 ( Desmopressin Oral Solution ) - Eton Pharmaceuticals ( NASDAQ:ETON )
- NDA submitted for the treatment of central diabetes insipidus - - Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch -
Hello Group Files Annual Report on Form 20-F for Fiscal Year 2024 - Hello Gr ( NASDAQ:MOMO )
BEIJING, April 28, 2025 /PRNewswire/ -- Hello Group Inc. MOMO ( "Hello Group" or the "Company" ) , a leading mobile social and entertainment platform in China, today filed with the U.S. Securities and Exchange Commission its annual report on Form 20-F for the fiscal year ended December 31, 2024.
As Tariffs Bite Apple, Samsung's Global Manufacturing Network Gains Edge In US-China Trade War - Samsung Electronics Co ( OTC:SSNLF )
As trade tensions between the U.S. and China escalate, Samsung Electronics SSNLF may hold a critical advantage over rival Apple Inc. AAPL through its diversified global manufacturing network.
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research ( AACR ) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax - Ascentage Pharma Group ( NASDAQ:AAPG )
ROCKVILLE, Md. and SUZHOU, China, April 28, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma AAPG HKEX: 6855 ) ) , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today ...
G2 Continues to Expand New Surface Gold Discovery and Provides Exploration Update - G2 Goldfields ( OTC:GUYGF )
G2 drills 41m @ 1.2 g/t Au & 50m @ 1.1 g/t Au and continues to expand significant new gold discovery Regional soil sampling surveys and mapping continue to generate high value drill targets Scout drilling at the Peters Mine property is underway with four holes completed
Cannara Biotech Delivers Record Q2 Results as National Expansion Accelerates - Cannara Biotech ( OTC:LOVFF )
Record Revenue: Net revenues of $26.6 million in Q2 2025, a 35% increase compared to $19.7 million in Q2 2024, driven by national brand growth and product innovation. Record Profitability: Gross profit before fair value adjustments rose 52% to $10.8 million in Q2 2025 from $7.1 million in Q2 ...
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, April 28, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. CSTL, a company improving health through innovative tests that guide patient care, today announced its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders.
GetYourGuide Elevates Experiences with New Tools, Previews Shows & Events
The #1 experience app releases suite of features to help experience operators "step into the spotlight" with a global audience
Village Farms International Takes Top Honors at the 2025 Stevie® Awards
Awards Spotlight Village Farms International's Visionary Leadership, Global Growth, and Commitment to Sustainable Innovation Awards Spotlight Village Farms International's Visionary Leadership, Global Growth, and Commitment to Sustainable Innovation ...
